After the non-approved stamp for Vanda Pharmaceuticals a typical anti-psychotic drug “Fanapta” by FDA “United States Food and Drug” administration in last October, it was anticipated that the drug was not effective and efficient as other medicines available for schizophrenia patients in the market like Johnson & Johnson’s “risperidone”, but seems like it was not the case just like other different anti-psychotic drugs Vanda Pharmaceuticals Inc. has to include a boxed warning, an advice to the doctors and patients about the growing risk of death, if the medicine is to be used by old aged people with cognitive function related neurosis behavioral problems, after the addition of the warning FDA has approved the drug by Vanda Pharmaceuticals Inc. The drug will be used for the treatment of schizophrenia, causing an eight-fold rise in the embattled drug-maker’s shares.
Comparing to other drugs available in the market for severe mental disorders which have many side effects, Vanda Pharmaceuticals Inc anti-psychotic medicine “Fanapta” seems like a safe substitute which include mild weight increase and blood sugar level, whereas company has stated that “Fanapt” does cause a mild increase in weight, but certainly does not cause any medically imperative increases in cholesterol or in blood sugar.
Pharmaceuticals Inc. Sanofi-Aventis SA, sold it rights to Titan Pharmaceuticals Inc. a California based company in 1996 afterwards Novartis AG was licensed by Titan Pharmaceuticals Inc, where as in 2004 Vanda Pharmaceuticals Inc. has acquired the rights from the Switzerland-based company Basel.
Comments